The company has spent about $1.8 billion bringing the drug to market, and around $975 million of these funds came from Mann's personal wealth. Afrezza's dry-powder formulation of insulin will ...

An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...

The INHALE-1 study is a 26-week, open-label clinical trial ... a planned meeting with the FDA, a potential sNDA submission and the potential expanded use of Afrezza that involves risks and ...

The U.S. Food and Drug Administration has approved inhalable insulin to help patients control their blood sugar levels. ManKind Corporation's Afrezza is a fast-acting form of insulin intended for ...

Mumbai-based pharmaceutical giant Cipla will distribute and market the drug in India. Inhaled from the mouth at the beginning of a meal, Afrezza dissolves rapidly into the lungs and delivers ...

This established the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. The company plans to meet with the FDA regarding a potential supplemental new drug application ...